Alkermes Plc Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Alkermes Plc Reports Third Quarter 2018 Financial Results
October 24, 2018 8:54 AM EDT
Credit Suisse analyst Vamil Divan lowered the price target on Alkermes (NASDAQ: ALKS) to $47.00 (from $51.00) while maintaining an Outperform rating following Q3.
Divan modestly reduces their sales estimates for Vivitrol and Aristada and also increase some of their expense assumptions... More
October 23, 2018 7:05 AM EDT
Alkermes (NASDAQ: ALKS) reported Q3 EPS of $0.07, $0.15 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $248.7 million versus the consensus estimate of $236.7 million.
"Our solid results in the quarter were in-line with expectations, driven by the growth of our proprietary commercial products, the continued strength of our royalty and manufacturing business, and the important investments we are making in our late-stage pipeline and commercial... More
